Single-shot COVID-19 vaccine protects non-human primates
Findings lay groundwork for clinical development program

Date:
July 30, 2020
Source:
Beth Israel Deaconess Medical Center
Summary:
A leading COVID-19 vaccine candidate raised neutralizing antibodies
and robustly protected non-human primates (NHPs) against SARS-CoV-2,
the virus that causes COVID-19.



FULL STORY ==========================================================================
The development of a safe and effective vaccine will likely be required
to end the COVID-19 pandemic. A group of scientists, led by Beth Israel Deaconess Medical Center (BIDMC) immunologist Dan H. Barouch, MD, PhD,
now report that a leading candidate COVID-19 vaccine developed at BIDMC
in collaboration with Johnson & Johnson raised neutralizing antibodies
and robustly protected non- human primates (NHPs) against SARS-CoV-2,
the virus that causes COVID-19. This study builds on the team's previous results and is published in the journal Nature.


========================================================================== "This vaccine led to robust protection against SARS-CoV-2 in rhesus
macaques and is now being evaluated in humans," said Barouch, who is
Director of BIDMC's Center for Virology and Vaccine Research.

The vaccine uses a common cold virus, called adenovirus serotype 26
(Ad26), to deliver the SARS-CoV-2 spike protein into host cells,
where it stimulates the body to raise immune responses against the
coronavirus. Barouch has been working on the development of a COVID-19
vaccine since January, when Chinese scientists released the SARS-CoV-2
genome. Barouch's group, in collaboration with Johnson & Johnson,
developed a series of vaccine candidates designed to express different
variants of the SARS-CoV-2 spike protein, which is the major target for neutralizing antibodies.

Barouch and colleagues conducted a study in 52 NHPs, immunizing 32 adult
rhesus macaques with a single dose of one of seven different versions of
the Ad26- based vaccine, and giving 20 animals sham vaccines as placebo controls. All vaccinated animals developed neutralizing antibodies
following immunization.

Six weeks after the immunization, all animals were exposed to
SARS-CoV-2. All 20 animals that received the sham vaccine became infected
and showed high levels of virus in their lungs and nasal swabs. Of the
six animals that received the optimal vaccine candidate, Ad26.COV2.S,
none showed virus in their lungs, and only one animal showed low levels
of virus in nasal swabs.

Moreover, neutralizing antibody responses correlated with protection, suggesting that this biomarker will be useful in the clinical development
of COVID-19 vaccines for use in humans.

"Our data show that a single immunization with Ad26.COV2.S robustly
protected rhesus macaques against SARS-CoV-2 challenge," said Barouch,
who is also the William Bosworth Castle Professor of Medicine at Harvard Medical School, a member of the Ragon Institute of MGH, MIT, and Harvard,
and a co-leader of the vaccine working group of the Massachusetts
Consortium on Pathogen Readiness. "A single-shot immunization has
practical and logistical advantages over a two- shot regimen for global deployment and pandemic control, but a two-shot vaccine will likely be
more immunogenic, and thus both regimens are being evaluated in clinical trials. We look forward to the results of the clinical trials that will determine the safety and immunogenicity, and ultimately the efficacy,
of the Ad26.COV2.S vaccine in humans." Investigators at Beth Israel
Deaconess Medical Center (BIDMC) and other institutions have initiated
a first-in-human Phase 1/2 clinical trial of the Ad26.COV2.S vaccine
in healthy volunteers. Kathryn E. Stephenson, MD, MPH, is the principal investigator for the trial at BIDMC, which is funded by Janssen Vaccines & Prevention, B.V., a pharmaceutical research arm of Johnson & Johnson.

Pending clinical trial outcomes, the Ad26.COV2.S vaccine is on track to
start a phase 3 efficacy trial in 30,000 participants in September.

Co-authors included Noe D. Mercado, Abishek Chandrashekar, Jingyou Yu,
Jinyan Liu, Lauren Peter, Katherine McMahan, Lisa H. Tostanoski, Esther
A. Bondzie, Gabriel Dagotto, Makda S. Gebre, Xuan He, Emily Hoffman,
Catherine Jacob-Dolan, Marinela Kiriloya, Zhenfen Li, Zijin Lin, Shant
H. Mahrokhian, Lori F.

Maxfield, Felix Nampanya, Ramya Mityanandam, Joseph P. Nkolola, Shivanai
Patel, John D. Ventura, Kaylee Verrignton and Huahua Wan of BIDMC; Lucy
Rutten, Rinke Bos, Danielle van Manan, Jort Vellinga, Jerome Custers,
Johannes P. Langedijk, Ted Kwaks, Paul Stoffels, Mathai Mammen, Johan
Van Hoof and Hanneke Schuitemaker of Janssen Vaccines & Prevention BV;
Carolin Loos, Caroline Atyeo, Stephanie Fischinger, John S. Burke,
Jared Feldman, Blake M. Hauser, Timothy M.

Caradonna, Aaron G. Schmidt and Galit Alter of the Ragon Institute
of MGH, MIT, and Harvard; Douglas A. Lauffenburger of Massachusetts
Institute of Technology; David Martinez and Ralph S. Baric of University
of North Carolina at Chapel Hill; Laurent Pessaint, Alex Van Ry, Kelvin
Blade, Amanda Strasbaugh, Mehtap Cabus, Renita Brown, Anthony Cook,
Serge Zouantchangadou, Elyse Teow, Hanne Anderson, and Mark G. Lewis of Bioqual; and Yongfei Cai and Bing Chen of Children's Hospital.

The authors declare no competing financial interests. Barouch, Zahn,
Wegman, Rutten, Bos, Manan, Vellinga, Custers, Langedijk, Kwaks, and Schuitemaker are co-inventors on related vaccine patents. Zahn, Wegman,
Rutten, Bos, Manan, Vellinga, Custers, Langedijk, Kwaks, Stoeffels,
Mammen, Van Hoof, and Schuitemaker are employees of Janssen Vaccines & Prevention BV and hold stock in Johnson & Johnson.

This project was funded in part by the Department of Health and Human
Services Biomedical Advanced Research and Development Authority (BARDA)
under contract HHS0100201700018C. We also acknowledge support from Janssen Vaccines & Prevention BV, the Ragon Institute of MGH, MIT, and Harvard,
Mark and Lisa Schwartz Foundation, Massachusetts Consortium on Pathogen Readiness (MassCPR), and the National Institutes of Health (OD024917,
AI129797, AI124377, AI128751, AI126603 to D.H.B.; AI007151 and AI152296
to D.R.M.; AI146779 to A.G.S.; 272201700036I-0-759301900131-1, AI100625, AI110700, AI132178, AI149644, AI108197 to R.S.B.). We also acknowledge
a Burroughs Wellcome Fund Postdoctoral Enrichment Program Award to D.R.M.


========================================================================== Story Source: Materials provided by
Beth_Israel_Deaconess_Medical_Center. Note: Content may be edited for
style and length.


========================================================================== Journal Reference:
1. Noe B. Mercado, Roland Zahn, Frank Wegmann, Carolin Loos, Abishek
Chandrashekar, Jingyou Yu, Jinyan Liu, Lauren Peter, Katherine
McMahan, Lisa H. Tostanoski, Xuan He, David R. Martinez, Lucy
Rutten, Rinke Bos, Danielle van Manen, Jort Vellinga, Jerome
Custers, Johannes P. Langedijk, Ted Kwaks, Mark J. G. Bakkers,
David Zuijdgeest, Sietske K. Rosendahl Huber, Caroline Atyeo,
Stephanie Fischinger, John S. Burke, Jared Feldman, Blake M. Hauser,
Timothy M. Caradonna, Esther A. Bondzie, Gabriel Dagotto, Makda
S. Gebre, Emily Hoffman, Catherine Jacob-Dolan, Marinela Kirilova,
Zhenfeng Li, Zijin Lin, Shant H. Mahrokhian, Lori F.

Maxfield, Felix Nampanya, Ramya Nityanandam, Joseph P. Nkolola,
Shivani Patel, John D. Ventura, Kaylee Verrington, Huahua Wan,
Laurent Pessaint, Alex Van Ry, Kelvin Blade, Amanda Strasbaugh,
Mehtap Cabus, Renita Brown, Anthony Cook, Serge Zouantchangadou,
Elyse Teow, Hanne Andersen, Mark G.

Lewis, Yongfei Cai, Bing Chen, Aaron G. Schmidt, R. Keith Reeves,
Ralph S. Baric, Douglas A. Lauffenburger, Galit Alter, Paul
Stoffels, Mathai Mammen, Johan Van Hoof, Hanneke Schuitemaker, Dan
H. Barouch. Single-shot Ad26 vaccine protects against SARS-CoV-2
in rhesus macaques. Nature, 2020; DOI: 10.1038/s41586-020-2607-z ==========================================================================

Link to news story: https://www.sciencedaily.com/releases/2020/07/200730110112.htm

--- up 2 weeks, 1 day, 1 hour, 55 minutes
* Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1337:3/111)